Vaccine trials inject hope into koala's future

Jul 16, 2007

The first Australian trials of a vaccine developed by Queensland University of Technology that could save Australia's iconic koala from contracting chlamydia are planned to begin later this year.

Professor Peter Timms, from QUT's Institute of Health and Biomedical Innovation, said chlamydia was a major threat to the continued survival of koalas with almost all populations affected by the disease.

"The trial is planned to begin before the end of the year and will test the vaccine's ability to induce a good immune response in the koala against chlamydia," he said.

"Assuming that this first trial is successful, then future trials can determine if this immune response is able to protect the koalas against chlamydial disease.

"We've been able to develop the vaccine for koalas as a result of our studies on the development of human chlamydial vaccines done in the mouse model. We have identified several novel vaccine proteins that we hope will protect koalas as well."

Professor Timms said chlamydia in koalas was a significant cause of infertility, urinary tract infections, and inflammation in the lining of the eye that often led to blindness.

"The numbers of koalas with chlamydia seems to be increasing," he said.

"As much as 40-50 per cent of koalas coming into care in both Queensland and NSW are showing clinical signs of the disease and it seems to be getting worse."

The vaccine will be administered to a small number of koalas via an injection either under the skin or intramuscularly.

"The first phase of the trial will run for between six and 12 months," he said.

"We will have initial results within the first six months but we will continue to monitor the koalas for 12 months to determine how long the vaccine stimulates an immune response in the koalas and whether or not a booster shot is required.

"There is no danger that a koala without chlamydia will contract the disease from the vaccine."

Professor Timms said the vaccine trial was a significant step in the right direction in fighting the threat of chlamydia in koalas.

QUT's koala vaccine team also includes Professor Ken Beagely and PhD student Asad Sukar.

"While we have funding for the initial trial we are hoping to attract additional financial support for us to be able to continue this important work," he said.

"We seem to be doing good science but we need more funding. We are looking for corporate or individual support to fund further research in this area."

Professor Timms said by investing in chlamydia research, people were giving hope to the future survival of koalas.


Source: Queensland University of Technology

Explore further: FDA OKs Cubist antibiotic for serious infections

add to favorites email to friend print save as pdf

Related Stories

Vaccine for koala chlamydia close

Jul 17, 2008

Professors Peter Timms and Ken Beagley from Queensland University of Technology's Institute of Health and Biomedical Innovation (IHBI) said the vaccinated koalas, which are at Brisbane's Lone Pine Koala Sanctuary, were mounting ...

World-first research will save koalas

Apr 09, 2013

The "holy grail" for understanding how and why koalas respond to infectious diseases has been uncovered in an Australian-led, world-first genome mapping project.

Fears for koalas as study reveals 'marked decline'

Sep 22, 2011

Australia's much-loved koala is under increasing threat and should be considered a vulnerable species, an official report found Thursday, with habitat loss seeing their numbers plunge.

Animals linked to human Chlamydia pneumoniae

Feb 22, 2010

Animals have been found to have infected humans sometime in the past with the common respiratory disease Chlamydia pneumoniae, according to Queensland University of Technology infectious disease expert Profes ...

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

2 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.